{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:07:50Z","timestamp":1784092070717,"version":"3.55.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Response to neoadjuvant PD-1 inhibitor plus chemotherapy in locally advanced esophagogastric adenocarcinoma varies widely, and tumor biomarkers alone do not fully explain the variation. We developed an integrated Body Composition and Immunonutritional Signature (BCIS) from pretreatment CT body composition and routine blood markers, and tested whether it predicts pathological response, immune-related adverse events (irAEs), and survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From four tertiary hospitals in Hebei Province, China, we enrolled 720 patients with histologically confirmed gastric or gastroesophageal junction (Siewert II\/III) adenocarcinoma treated between 2019 and 2023 with neoadjuvant PD-1 inhibitor plus SOX or XELOX followed by D2 gastrectomy. BCIS was a 0\u201310 additive score from ten prespecified adverse host features. Analyses included logistic regression, restricted cubic spline (RCS) modeling, multivariable Cox regression, DeLong tests for nested AUC comparisons, decision-curve analysis, eleven sensitivity scenarios, and collinearity checks by Spearman correlation and variance inflation factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>BCIS classified 243 (33.8%) patients as favorable, 303 (42.1%) as intermediate, and 174 (24.2%) as unfavorable. Major pathological response (MPR) rates dropped sharply across strata (64.2%, 39.6%, 21.8%; P-trend&amp;lt;0.001). After adjusting for age, sex, cT\/cN, PD-L1 CPS, MMR status, EGJ origin, and regimen, every BCIS point cut the odds of MPR by roughly 40% (adjusted OR\u00a0=\u00a00.61, 95% CI 0.55\u20130.68, P&amp;lt;0.001) and pCR by close to half (adjusted OR\u00a0=\u00a00.55, 95% CI 0.46\u20130.66, P&amp;lt;0.001). RCS modeling flagged CRP and CAR as nonlinear; BCIS itself was strictly linear. Adding BCIS to a clinical baseline lifted overall AUC for MPR from 0.597 to 0.710 (DeLong P&amp;lt;0.001) and external AUC from 0.588 to 0.704. At 42.5 months\u2019 median follow-up, each BCIS point raised the hazard of progression by 53% (adjusted HR\u00a0=\u00a01.53, 95% CI 1.44\u20131.63) and of death by 38% (adjusted HR\u00a0=\u00a01.38, 95% CI 1.29\u20131.47; both P&amp;lt;0.001). Direction of effect held across every prespecified subgroup (P-interaction&amp;gt;0.10 throughout) and all eleven sensitivity scenarios.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>BCIS is independently associated with pathological response and survival under neoadjuvant PD-1-based immunochemotherapy and adds discrimination beyond tumor-centered biomarkers and clinical staging. Because every component comes from routine pretreatment workup at no extra cost, BCIS could feasibly inform prehabilitation, toxicity surveillance, and shared decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1875482","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:47:10Z","timestamp":1784090830000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["An integrated body composition\u2013 immunonutritional signature for predicting immunotherapy response and prognosis in gastric cancer: a multicenter retrospective cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Fang","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pathology, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zheng","sequence":"additional","affiliation":[{"name":"The Third Department of Surgery, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Hebei Key Laboratory of Precision Diagnosis and Comprehensive Treatment of Gastric Cancer","place":["Shijiazhuang, Hebei, China"]},{"name":"Big Data Analysis and Mining Application for Precise Diagnosis and Treatment of Gastric Cancer, Hebei Provincial Engineering Research Center","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghai","family":"Guo","sequence":"additional","affiliation":[{"name":"The Third Department of Surgery, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Hebei Key Laboratory of Precision Diagnosis and Comprehensive Treatment of Gastric Cancer","place":["Shijiazhuang, Hebei, China"]},{"name":"Big Data Analysis and Mining Application for Precise Diagnosis and Treatment of Gastric Cancer, Hebei Provincial Engineering Research Center","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peigang","family":"Yang","sequence":"additional","affiliation":[{"name":"The Third Department of Surgery, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Hebei Key Laboratory of Precision Diagnosis and Comprehensive Treatment of Gastric Cancer","place":["Shijiazhuang, Hebei, China"]},{"name":"Big Data Analysis and Mining Application for Precise Diagnosis and Treatment of Gastric Cancer, Hebei Provincial Engineering Research Center","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Shijiazhuang People\u2019s Hospital","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Baoding Central Hospital","place":["Baoding, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjiang","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Hengshui People\u2019s Hospital","place":["Hengshui, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Tian","sequence":"additional","affiliation":[{"name":"The Third Department of Surgery, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Hebei Key Laboratory of Precision Diagnosis and Comprehensive Treatment of Gastric Cancer","place":["Shijiazhuang, Hebei, China"]},{"name":"Big Data Analysis and Mining Application for Precise Diagnosis and Treatment of Gastric Cancer, Hebei Provincial Engineering Research Center","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Zhao","sequence":"additional","affiliation":[{"name":"The Third Department of Surgery, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Hebei Key Laboratory of Precision Diagnosis and Comprehensive Treatment of Gastric Cancer","place":["Shijiazhuang, Hebei, China"]},{"name":"Big Data Analysis and Mining Application for Precise Diagnosis and Treatment of Gastric Cancer, Hebei Provincial Engineering Research Center","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12516","article-title":"The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-022-01331-8","article-title":"Japanese gastric cancer treatment guidelines 2021 (6th edition)","volume":"26","year":"2023","journal-title":"Gastric Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0137","article-title":"Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer","volume":"4","author":"Caan","year":"2018","journal-title":"JAMA Oncol"},{"key":"B10","article-title":"Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients","volume":"85","author":"Onodera","year":"1984","journal-title":"Nihon Geka Gakkai Zasshi"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1061044","article-title":"Body composition parameters for predicting the efficacy of neoadjuvant chemotherapy with immunotherapy for gastric cancer","volume":"13","author":"Lin","year":"2022","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0527-y","article-title":"A multicenter study of body mass index in cancer patients treated with anti-PD-1\/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable","volume":"7","author":"Cortellini","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31778","article-title":"The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy","volume":"125","author":"Bilen","year":"2019","journal-title":"Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1139\/H08-075","article-title":"A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care","volume":"33","author":"Mourtzakis","year":"2008","journal-title":"Appl Physiol Nutr Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0221-5","article-title":"Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade","volume":"25","author":"Wang","year":"2019","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11660","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7110","article-title":"Body composition change indices combined with prognostic nutritional index predict the clinical outcomes of patients with gastric cancer treated with immune checkpoint inhibitor","volume":"13","author":"Deng","year":"2024","journal-title":"Cancer Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-58498-2","article-title":"Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1\/PD-L1 checkpoint inhibitors: a multicenter real-life study","volume":"10","author":"Cortellini","year":"2020","journal-title":"Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13674","article-title":"Postoperative skeletal muscle loss as a prognostic indicator of clinical outcomes in patients with gastric cancer: a systematic review and meta-analysis","volume":"16","author":"Wang","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202411490","article-title":"Multimodal artificial intelligence-based virtual biopsy for diagnosing abdominal lavage cytology-positive gastric cancer","volume":"12","author":"Ding","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132408","article-title":"Impact of neoadjuvant treatment on body composition in patients with locally advanced gastric cancer","volume":"16","author":"Juez","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-2025-192","article-title":"Retrospective study on the prognostic prediction of inflammatory markers and the C-reactive protein\/albumin ratio in first-line immunotherapy for advanced HER2-negative gastric cancer patients","volume":"14","author":"Sun","year":"2025","journal-title":"Transl Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12573","article-title":"Evaluation of automated computed tomography segmentation to assess body composition and mortality associations in cancer patients","volume":"11","author":"Cespedes Feliciano","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1875482\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:47:18Z","timestamp":1784090838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1875482\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":25,"alternative-id":["10.3389\/fonc.2026.1875482"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1875482","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1875482"}}